Molecular Partners AG (0QXX.L)
CHF 3.4
(-5.82%)
CHF 3.4
(-5.82%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -59.51 Million CHF | -148.85% |
| 2022 | 117.5 Million CHF | 297.7% |
| 2021 | -60.66 Million CHF | -10.27% |
| 2020 | -59.58 Million CHF | -68.69% |
| 2019 | -33.7 Million CHF | 9.93% |
| 2018 | -36.11 Million CHF | -50.56% |
| 2017 | -24.69 Million CHF | -33.37% |
| 2016 | -17.52 Million CHF | -1666.21% |
| 2015 | 760 Thousand CHF | -134.22% |
| 2014 | -1.47 Million CHF | -63.27% |
| 2013 | 7.93 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -15.25 Million CHF | 44.12% |
| 2024 Q2 | -15.37 Million CHF | -35.11% |
| 2024 Q3 | -15.8 Million CHF | -9.22% |
| 2023 Q1 | -13.61 Million CHF | 0.74% |
| 2023 Q4 | -16.04 Million CHF | -37.17% |
| 2023 Q2 | -14.19 Million CHF | -4.28% |
| 2023 FY | - CHF | -148.85% |
| 2023 Q3 | -11.69 Million CHF | 17.6% |
| 2022 Q3 | -13.85 Million CHF | -149.33% |
| 2022 Q1 | 153.26 Million CHF | 1113.5% |
| 2022 FY | - CHF | 297.7% |
| 2022 Q4 | -13.71 Million CHF | 1.02% |
| 2022 Q2 | -5.55 Million CHF | -103.63% |
| 2021 Q2 | -15.59 Million CHF | 12.68% |
| 2021 FY | - CHF | -10.27% |
| 2021 Q1 | -17.86 Million CHF | 7.35% |
| 2021 Q3 | -12.17 Million CHF | 21.94% |
| 2021 Q4 | -15.12 Million CHF | -24.2% |
| 2020 Q4 | -19.28 Million CHF | -33.4% |
| 2020 Q1 | -11.52 Million CHF | 4.05% |
| 2020 Q2 | -10.13 Million CHF | 12.09% |
| 2020 Q3 | -14.45 Million CHF | -42.68% |
| 2020 FY | - CHF | -68.69% |
| 2019 Q1 | -5.62 Million CHF | 53.81% |
| 2019 FY | - CHF | 9.93% |
| 2019 Q4 | -12.01 Million CHF | 0.0% |
| 2019 Q3 | -12.01 Million CHF | -113.64% |
| 2019 Q2 | -5.62 Million CHF | 0.0% |
| 2018 Q2 | -6.1 Million CHF | 0.0% |
| 2018 FY | - CHF | -50.56% |
| 2018 Q4 | -12.17 Million CHF | 0.0% |
| 2018 Q3 | -12.17 Million CHF | -99.5% |
| 2018 Q1 | -6.1 Million CHF | -42.2% |
| 2017 Q1 | -6.43 Million CHF | -5.13% |
| 2017 FY | - CHF | -33.37% |
| 2017 Q4 | -4.29 Million CHF | 0.0% |
| 2017 Q3 | -4.29 Million CHF | 55.97% |
| 2017 Q2 | -9.74 Million CHF | -51.39% |
| 2016 Q3 | -4.38 Million CHF | 27.63% |
| 2016 Q2 | -6.05 Million CHF | -205.63% |
| 2016 Q4 | -6.12 Million CHF | -39.76% |
| 2016 FY | - CHF | -1666.21% |
| 2016 Q1 | -1.98 Million CHF | -563.47% |
| 2015 Q4 | -298.5 Thousand CHF | -112.46% |
| 2015 Q3 | 2.39 Million CHF | 172.18% |
| 2015 Q1 | -205.2 Thousand CHF | 22.4% |
| 2015 FY | - CHF | -134.22% |
| 2015 Q2 | -3.31 Million CHF | -1516.86% |
| 2014 Q4 | -264.44 Thousand CHF | -126.29% |
| 2014 FY | - CHF | -63.27% |
| 2014 Q2 | 955.47 Thousand CHF | -0.0% |
| 2014 Q1 | 955.47 Thousand CHF | 359.57% |
| 2014 Q3 | 1 Million CHF | 5.28% |
| 2013 Q4 | -368.09 Thousand CHF | -118.56% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q2 | 1.98 Million CHF | 0.0% |
| 2013 Q3 | 1.98 Million CHF | 0.0% |
| 2013 Q1 | 1.98 Million CHF | 0.0% |
| 2012 Q4 | 1.98 Million CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -108.2 Million CHF | 44.996% |
| Tecan Group AG | 205.57 Million CHF | 128.951% |
| Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 175.17% |
| Basilea Pharmaceutica AG | 29.49 Million CHF | 301.78% |
| Bachem Holding AG | 163.27 Million CHF | 136.451% |
| Siegfried Holding AG | 241.21 Million CHF | 124.673% |